Takeda Pharmaceuticals America, Inc. lobbied on 8 issues. See lobbying
Its wordsWhat does this committee say it is for?
No published list of positions
This committee’s site publishes no list of positions we could read, and we found no statement of why it exists. We do not write one for it.
Who it gives toWhich candidates and committees get its money?
Each part reads different filings, so counts and totals can differ.
Party support distribution$147K to 47 candidates
Direct PAC contributions and independent expenditures explicitly reported as support, by the party of the candidate they went to.
For candidates $147,000
Republican 47%
Democratic 43%
Support by the party of the candidate
Party of the candidate
Candidates
Direct
Independent
Amount
Share
Republican
22
$68,500
$0
$68,500
47%
Democratic
18
$62,500
$0
$62,500
43%
Other or unresolved
7
$16,000
$0
$16,000
11%
Shown support
47
$147,000
$0
$147,000
100%
Contributions are reported money, not endorsements; a PAC giving to both parties is common.
Who this PAC gave to$272,000 in 104 payments
Every contribution on line 23 of the committee’s own Schedule B, which is the filing its summary totals are built from. That line covers federal candidates, party committees and other political committees alike, so a super PAC funding other super PACs appears here rather than under candidate giving.
By recipient
Line 23 contributions by kind and party of recipient
Recipient
Count
Amount
Democratic candidates
18
$62.5K · 23%
Republican candidates
22
$68.5K · 25%
Other or unresolved candidates
7
$16K · 5.8%
Democratic party committees
1
$10K · 3.6%
Other PACs and committees
21
$117.5K · 43%
All recipients
69
$274.5K
By the candidate’s state
Contributions to candidates by the candidate’s state
State
Candidates
Amount
Massachusetts
5
$20K
Illinois
4
$18.5K
California
8
$18K
Kentucky
1
$10K
Minnesota
1
$10K
Virginia
2
$7.5K
Georgia
2
$7K
North Carolina
2
$6K
The largest 8 of 27 states.
Recipients 69
Show candidate activity and the money network
Candidate and election activity as the recipients filed it
Thomas Earl Emmer Jr.2 receipts, latest Mar 13, 2026Emmer for Congress · H4MN06087$10K
Bradley S. Schneider3 receipts, latest Jun 22, 2026Schneider for Congress · H2IL10068$10K
S. Brett Brett Guthrie2 receipts, latest Mar 13, 2026Guthrie for Congress · H8KY02031$10K
Jake Auchincloss3 receipts, latest Mar 13, 2026Jake Auchincloss for Congress · H0MA04192$7.5K
Richard E. Neal1 receipt, latest Jun 5, 2025Richard E Neal for Congress Committee · H8MA02041$5K
Candidate contribution rows come from candidate committee Schedule A filings, the same rows the party chart above counts.
Committee money network
Money moving between this committee and other committees, matched on FEC committee ID rather than the name each filing was typed under. Both sides exclude memo entries. The figures here count each committee once, from the itemized transfers read for this section, so they will not match the payment counts under Who this PAC gave to.
Committees funding this one
Committees that reported giving to this one on their own Schedule A filings, grouped by the giver’s committee ID.
No committee-to-committee receipts were itemized this cycle.
Committees this one funds
Disbursements this committee itemized to another committee: candidate contributions, party transfers and payments alike, not contributions only.
Where the money came from $290,115 reported receipts
Itemized (over $200)Donors who have given more than $200 this cycle, so the FEC itemizes (names) them.$219,60676%
Largest donors
Pallavi Garg20 contributions, latest Aug 31, 2026 · HEAD OF US ONCOLOGY · TAKEDA PHARMACEUTICALS U.S.A. INC. · CAMBRIDGE, MA$8,064
Andrew G. Kaplan20 contributions, latest Aug 31, 2026 · SVP US PUBLIC AFFAIRS · TAKEDA PHARMACEUTICALS AMERICA INC. · CAMBRIDGE, MA$8,064
Julie Kim20 contributions, latest Aug 31, 2026 · REPRESENTATIVE DIRECTOR PRESIDENT AND · TAKEDA PHARMACEUTICALS U.S.A. INC. · CAMBRIDGE, MA$8,064
Andrew Plump20 contributions, latest Aug 31, 2026 · PRESIDENT RESEARCH AND DEVELOPMENT · TAKEDA DEVELOPMENT CENTER AMERICAS INC · CAMBRIDGE, MA$8,064
Kirsten T. Powell20 contributions, latest Aug 31, 2026 · VP US GOVERNMENT AFFAIRS · TAKEDA PHARMACEUTICALS AMERICA INC. · CAMBRIDGE, MA$8,064
Meena Subramanyam20 contributions, latest Aug 31, 2026 · VP GLOBAL PROGRAM LEADER · TAKEDA DEVELOPMENT CENTER AMERICAS INC · CAMBRIDGE, MA$8,064
Brandon J. Monk20 contributions, latest Aug 31, 2026 · SVP HEAD OF GASTROINTESTINAL & INFLAMM · TAKEDA PHARMACEUTICALS U.S.A. INC. · CAMBRIDGE, MA$7,052
Elizabeth Lewis20 contributions, latest Aug 31, 2026 · HEAD OF GLOBAL ONCOLOGY PATIENT VALUE · TAKEDA PHARMACEUTICALS AMERICA INC. · CAMBRIDGE, MA$6,300
Onelia A. Vera20 contributions, latest Aug 31, 2026 · HEAD COUNSEL GLOBAL MEDICAL PATIENT AC · TAKEDA PHARMACEUTICALS AMERICA INC. · CAMBRIDGE, MA$6,300
Laura E. Cline20 contributions, latest Aug 31, 2026 · VP THERAPEUTIC AREA POLICY AND PATIENT · TAKEDA PHARMACEUTICALS AMERICA INC. · CAMBRIDGE, MA$6,050
Jennifer Norton15 contributions, latest Mar 31, 2026 · SENIOR VICE PRESIDENT U.S. PATIENT AND · TAKEDA PHARMACEUTICALS AMERICA INC. · CAMBRIDGE, MA$5,952
Jennifer West13 contributions, latest Aug 31, 2026 · CHIEF INFORMATION SECURITY OFFICER · TAKEDA PHARMACEUTICALS AMERICA INC. · CAMBRIDGE, MA$5,184
A donor who gave several times appears once. The 12 largest donors by total given are listed. In all, 1,385 itemized contributions were filed this cycle, totaling $203.6K. FEC contributor lists are public records and cannot be used for commercial solicitation.
Unitemized ($200 or less)Donors who have given $200 or less this cycle, so the FEC does not itemize (name) them.$70,50924%
Total reported receipts $290,115
Every dollar the committee reported receiving this cycle, split by the source the FEC filing attributes it to. Open a source marked + to see who gave. FEC filings through Oct 14, 2026.
Who donated: where they live, their employers and jobs
Where the donors live $203,581 placed by state
Loading the map
Tap or hover over a state, or focus the map and use the arrow keys, to read its total. Ctrl or ⌘ and scroll to zoom.
under $8.1K
$8.1K+
$32.5K+
$73.2K+
$130.1K+
none
Top states
Top donor states
Name
Amount
Massachusetts1,383 contributions · 99.9%
$203,341
Connecticut1 contribution · <0.1%
$120
Virginia1 contribution · <0.1%
$120
By the state each contributor wrote on the filing. The FEC aggregates every Schedule A line together, so one committee or organization transfer can account for a whole state. Contributors who have given $200 or less this cycle are not itemized and cannot be placed on a map. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total.
Donors’ employers as filed
Donors’ employers
Employer as filed
Amount
Takeda Pharmaceuticals America INC701 contributions · 49% of ranked
$100,525
Takeda Pharmaceuticals U S A INC480 contributions · 34% of ranked
SpendingWhere does the money go?
How the spending splits $326,730 reported
Contributions to candidates and other committeesMoney given to federal candidates, party committees and other PACs.$323,50099%
VIEWPAC2 payments · latest Mar 13, 2026 · CONTRIBUTION$5,000
Operating expendituresThe committee's own running costs.$3,2301%
Paid to
Bank of America18 payments · latest Aug 31, 2026 · BANK FEES$2,775
Total reported disbursements $326,730
Every dollar this committee reported spending this cycle, split by the lines it reports against. Open a line to see who was actually paid on it. FEC filings through Oct 14, 2026.
What the payments were for $274,775 itemized
Given to othersContributions to other candidates, party committees, and PACs.$272,00099%
Filed as
CONTRIBUTION$272,000
Paid to
Republican Mainstreet Partnership PAC$10,000
Congressional Black Caucus PAC$10,000
CHC Bold PAC$10,000
New Democratic Coalition Action Fund$10,000
Moderate Democrats PAC$10,000
Massachusetts Democratic State Committee - FED Fund$10,000
Taxes, fees, and bank chargesPayroll and income taxes, filing fees, bank and merchant processing charges.$2,7751%
Filed as
BANK FEES$2,620
BANK FEE$155
Paid to
Bank of America$2,775
Total itemized disbursements $274,775
Every itemized payment the committee reported this cycle, sorted by what it said each one was for. The categories are ours; the wording they are matched against is the committee’s own. Open a category to read the filed descriptions and who was paid. FEC filings through Oct 14, 2026.
All 122 itemized payments filed this cycle. Spending below the itemization threshold is not filed line by line.
Largest vendors
Spending over time
$329.1K spent from Jan 2025 to Oct 2026. Most in one report: $73.6K, March 2026.
$329.1K
Jan 2025Oct 2026
The running total of what the committee’s FEC reports say it spent, independent expenditures included, with a point at the end of each report. The line is straight between reports because a report gives one total for its whole period.
What Takeda Pharmaceuticals America, Inc. lobbies on 2026 reports
Besides giving through its PAC, Takeda Pharmaceuticals America, Inc. pays lobbyists to press Congress and federal agencies. Each quarter it, or a firm it hires, files a public report under the Lobbying Disclosure Act saying which topics it worked on, what it spent, and whom it contacted. This is what those reports say.
Spent on lobbying in 2026
$3.5M
Quarterly reports read
26
Bills it named
19
Topics it lobbied on
Each report files its work under official topics. The bar shows how often each topic came up across the reports; open one to read what was filed under it. Naming a bill says the organization lobbied on it, not which side it took.
Health Issuesin 18 report entries · 13 bills named
In its own words
H.R. 9599 SECURE 340B Act, all pharmaceutical related provisions H.R. 5256 340B ACCESS Act, all pharmaceutical related provisions S. 2372 H.R. 4581 340B Patients Act of 2025, all pharmaceutical related provisions H.R. 8269 CLEAR LABELS Act, all pharmaceutical related provisions S. 2658 Medication Affordability and Patient Integrity Act, all pharmaceutical related provisions S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, all pharmaceutical related provisions S. 1040 Drug Competition Enhancement Act, all pharmaceutical related provisions S.1095 Stop STALLING Act, all pharmaceutical related provisions S. 1954 Biosimilar Red Tape Elimination Act, all pharmaceutical related provisions Drug Pricing: Policies pertaining to drug pricing not yet introduced Plasma: Policies or advocacy in the promotion of protecting access PBM Reform: Policies related to PBM not yet introduced (e.g., coverage, transparency, accumulators, etc) (Note: RFIs do not count) 340B: Policies related to 340B not specific to a piece of legislation PDUFA: Perscription Drug User Fee Act Global pharmaceutical supply chain operations and manufacturing locations Bayh-Dole march in rights policy issues
Clarify or reform the 340B program Value-based drug contracting Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) Drug pricing, including House and Senate draft bills Bayh-Dole march-in rights policy issues SECURE 340B Act (bill# not listed yet) Senate Finance Committee Drug Pricing RFI
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
S.891, Bipartisan Health Care Act;
Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) Drug pricing, including House and Senate draft bills Bayh-Dole march-in rights policy issues
Issues related to Plasma-Derived Therapies; Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to National Priority Voucher (CNPV) program.
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Medicare/Medicaidin 12 report entries · 7 bills named
In its own words
Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Medicare payment proposals Medicare telehealth proposals CMS Transparency in Coverage Final Rule (CMS-9915-F) Request for Regulatory Clarification with Medicare Part B Group (CMS) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on biosimilars related to IRA Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on orphan drugs related to the IRA Discussions on treatment of small molecule drugs related to IRA H.R.1 492, S. 832, EPIC Act of 2025 HR 4229 Protecting Patient Access to Cancer & Complex Therapies Act
Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Medicare payment proposals Request for Regulatory Clarification with Medicare Part B Group (CMS) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on orphan drugs related to the IRA Discussions on treatment of small molecule drugs related to IRA H.R.1 492, S. 832, EPIC Act of 2025 H.R. 946, Optimizing Research Progress Hope and New (ORPHAN) Cures Act HR 4229 Protecting Patient Access to Cancer & Complex Therapies Act
Taxation/Internal Revenue Codein 8 report entries · 1 bill named
In its own words
Administration's Global Tax Proposal Tax incentive issues as they relate to proposed global supply chain bills Discussions related to the repeal of the BEAT - provisions related to orphan drug tax credits
Issues related to tax reform; R&D tax credit; orphan drug tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Administration's Global Tax Proposal General issues around 2026 Reconciliation/Inbound Concerns
Issues related to tax reform; international taxation.
Reported twice a year by the lobbying filer. $144.6K is political giving that also appears in FEC filings.
DSCC$46.3K
Rep. Chris Pappas$9K
Janet Mills$7K
Katherine Clark Majority Fund$7K
Adrian Boafo$6.8K
Sen. Andy Kim$5K
Sen. Elissa Slotkin$5K
Dan Osborn$4.5K
Josh Turek$4K
Sen. Maggie Hassan$4K
Matched by name: these reports are filed for “TAKEDA PHARMACEUTICALS AMERICA, INC.”, found by searching “TAKEDA PHARMACEUTICALS AMERICA”. Lobbying and FEC records share no ID, so an organization that lobbies under another name is missed. Source: LDA.gov, accessed Oct 27, 2026. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
TAKEDA PHARMACEUTICALS AMERICA INC. POLITICAL ACTION COMMITTEE
Filings covered
Through Oct 14, 2026
Data source
FEC bulk filing data
Takeda Pharmaceuticals America Inc. PAC is registered with the Federal Election Commission as a PAC (qualified). It is a lobbyist/registrant PAC. Its FEC record names Takeda Pharmaceuticals America, Inc. as an affiliate. Official FEC summary: Federal Election Commission committee record.
Pages quoted 0 pages
No pages quoted
Nothing from this committee’s or its sponsor’s site is quoted yet.
Linked public records
No approved organization identity yet
The official FEC committee record remains available under Filings.
Value in Electing Women PACHybrid PAC (qualified) · Connected to MCMORRIS RODGERS WIN THE FUTURE FUND · 2 payments
$5K
$274.5K across 72 recipient committees, or 84% of everything this committee reports spending. The largest 12 are shown.
Built from FEC Schedule A and Schedule B filings for the selected cycle. A committee only appears here if the money was itemized under its FEC committee ID.
$69,783
Takeda Development Center Americas INC176 contributions · 15% of ranked
$29,538
Takeda Vaccines INC7 contributions · 0.7% of ranked
$1,400
TDC Americas3 contributions · 0.3% of ranked
$700
Takeda Pharma U S A6 contributions · 0.3% of ranked
$650
Takeda Pharmaceuticals USA INC7 contributions · 0.3% of ranked
$560
Baxalta U S INC2 contributions · <0.1% of ranked
$165
Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($70,509) are not itemized, so no employer or occupation is filed for them.
Donors’ occupations as filed
Donors’ occupations
Occupation as filed
Amount
Director Federal Government Affairs46 contributions · 4.5% of ranked
$9,120
Head Of US Oncology20 contributions · 4% of ranked
$8,064
President Research And Development20 contributions · 4% of ranked
$8,064
SVP US Public Affairs20 contributions · 4% of ranked
$8,064
VP Global Program Leader20 contributions · 4% of ranked
$8,064
Head Of Global Oncology Patient Value20 contributions · 3.1% of ranked
$6,300
VP Federal GOV Affairs Public Policy &15 contributions · 3% of ranked
$6,144
VP Therapeutic Area Policy And Patient20 contributions · 3% of ranked
$6,050
Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($70,509) are not itemized, so no employer or occupation is filed for them.
The people, firms and committees paid the most, across every kind of payment. Each share is of everything the committee reported spending this cycle, not only the itemized payments above. A payee that is itself a committee links to its own profile.
H.R.1 492 , S. 832, EPIC Act of 2025, all pharmaceutical related provisions H.R. 7837 Most Favored Patient Act f 2026, all pharmaceutical related provisions H.R. 4299 Protecting Patient Access to Cancer & Complex Therapies Act, all pharmaceutical related provisions H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act, all pharmaceutical related provisions P.L. 117-169 Inflation Reduction Act, all pharmaceutical related provisions IRA: Discussions on reform (non-H.R. 4299, e.g., Orphan Cures change, biosimilars, etc) IRA: Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Medicare: Proposals enhance patient access (e.g., protected classes, telehealth, coverage) Medicare: Proposals related to payment proposals (e.g., Part D, Part B, ASP, transparency) Medicaid: Proposals related to access or pricing GLOBE CMMI Model Executive Order
General issues related to Medicare and Medicaid, including: Part D Medicare Program;
Medicare Part B reimbursement;
CMMI Drug Pricing Demonstration Programs;
Drug Pricing;
Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.